Healthcare Industry News: Johnson & Johnson Vision
News Release - November 9, 2017
Johnson & Johnson Vision Announces TearScience LipiScan(R) and LipiFlow(R) Now Available in More Than 800 Eye Care Practices to Image Meibomian Glands and Treat Meibomian Gland DysfunctionMeibomian Gland Dysfunction (MGD) is a primary cause of dry eye disease, which impacts more than 340 million people globally
LipiScan® and LipiFlow® technologies offer rapid, effective solutions for optometry and ophthalmology practices in North America
SANTA ANA, Calif., Nov. 9, 2017 -- (Healthcare Sales & Marketing Network) -- TearScience, now a part of Johnson & Johnson Vision, announced today at the American Academy of Ophthalmology (AAO) 2017 Meeting its LipiScan® and LipiFlow® technologies are now available in more than 800 optometrist and ophthalmologist offices in the U.S. and Canada.
Dry eye affects more than 340 million people around the world.i MGD is a leading cause of dry eye,ii found in an estimated 86% of dry eye patients.iii The LipiFlow® System is a best-in-class medical device treatment for MGD shown to improve mean gland function and dry eye symptoms. The efficacy of LipiFlow® is supported by 30 peer-reviewed reports. LipiScan® is the first and only dedicated rapid high definition gland imager.
"We're proud to announce this milestone—it's a significant measure of our commitment to effectively treat this leading cause of dry eye," said Joe Boorady, President and CEO, TearScience. "In joining forces with Johnson & Johnson Vision, we'll connect more with the optometry and ophthalmology communities to assure they have the tools needed to optimize ocular surface health for millions of patients."
"A healthy ocular surface is important for contact lenses or for cataract procedures," said Tom Frinzi, Worldwide President, Surgical Vision, Johnson & Johnson Vision. "TearScience technology is proven to treat one of the leading causes of dry eye, which is directly aligned with our product portfolio and our commitment to improve and restore sight for patients."
For additional information on how TearScience improves meibomian gland function and symptoms for patients with MGD worldwide, please visit www.TearScience.com.
Johnson & Johnson Vision
Johnson & Johnson Vision, through its operating companies, is committed to improving and restoring sight for patients worldwide. Since debuting the world's first disposable soft contact lens in 1987, Johnson & Johnson Vision Care, Inc. has been helping patients see better through their world-leading ACUVUE® Brand Contact Lenses portfolio. In 2017, with the addition of Abbott Medical Optics, Inc., the Johnson & Johnson Surgical Vision business, Johnson & Johnson invested further in eye health by expanding into cataract surgery, laser refractive surgery (LASIK) and consumer eye health. Serving more than 60 million patients a day across 103 countries, Johnson & Johnson Vision is committed to helping more people in more places improve or restore their sight. Dual headquartered in Jacksonville, Florida, and Santa Ana, California, Johnson & Johnson Vision has more than 10,000 employees worldwide.
© 2017 Abbott Medical Optics, Inc. LipiScan and LipiFlow are trademarks owned by or licensed to Abbott Medical Optics, Inc., its subsidiaries or affiliates. All other trademarks are the intellectual property of their respective owners.
i MarketScope: 2016 Dry Eye Products Report: A Global Market Analysis for 2015 to 2021: pg. 56.
ii Nichols KK, Foulks GN, Bron AJ, et al. The International Workshop on Meibomian Gland Dysfunction: Executive Summary. Investigative Ophthalmology & Visual Science. 2011;52(4):1922-1929.
iii Lemp MA, Crew LA, Bron AJ, et al. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea. 2012;31(5):472-478.
Source: Johnson & Johnson
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.